KR102042015B1 - 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법 - Google Patents

폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법 Download PDF

Info

Publication number
KR102042015B1
KR102042015B1 KR1020137033193A KR20137033193A KR102042015B1 KR 102042015 B1 KR102042015 B1 KR 102042015B1 KR 1020137033193 A KR1020137033193 A KR 1020137033193A KR 20137033193 A KR20137033193 A KR 20137033193A KR 102042015 B1 KR102042015 B1 KR 102042015B1
Authority
KR
South Korea
Prior art keywords
hours
peptide
pharmaceutical composition
induced
angioedema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137033193A
Other languages
English (en)
Korean (ko)
Other versions
KR20140056185A (ko
Inventor
율리아 에이. 코마로바
우즈마 사킵
스티븐 엠. 보글
아스라 비. 말릭
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20140056185A publication Critical patent/KR20140056185A/ko
Application granted granted Critical
Publication of KR102042015B1 publication Critical patent/KR102042015B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020137033193A 2011-06-13 2012-06-13 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법 Expired - Fee Related KR102042015B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
US61/496,409 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Publications (2)

Publication Number Publication Date
KR20140056185A KR20140056185A (ko) 2014-05-09
KR102042015B1 true KR102042015B1 (ko) 2019-11-07

Family

ID=47357694

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033193A Expired - Fee Related KR102042015B1 (ko) 2011-06-13 2012-06-13 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법

Country Status (15)

Country Link
US (2) US9248198B2 (enExample)
EP (1) EP2717897B1 (enExample)
JP (1) JP6042425B2 (enExample)
KR (1) KR102042015B1 (enExample)
CN (2) CN106188232B (enExample)
AU (1) AU2012271781C1 (enExample)
BR (1) BR112013032108B1 (enExample)
CA (1) CA2838662C (enExample)
DK (1) DK2717897T3 (enExample)
ES (1) ES2633343T3 (enExample)
IL (1) IL229771B (enExample)
MX (1) MX349146B (enExample)
PL (1) PL2717897T3 (enExample)
WO (1) WO2012174028A2 (enExample)
ZA (1) ZA201309161B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법
DK3265110T3 (da) * 2015-03-02 2020-10-19 The Board Of Trustees Of The Univ Of Illionis Peptider til inhibering af angiogenese
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
US20230218710A1 (en) * 2020-04-15 2023-07-13 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2545062A1 (en) * 2003-11-06 2005-05-26 Research Development Foundation Selective inhibitors of nuclear factor-kb activation and uses thereof
KR101260717B1 (ko) * 2003-12-03 2013-05-09 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 튜불린 저해제
KR20080075494A (ko) * 2005-09-21 2008-08-18 다스크 테크날러지, 엘엘씨 장기 및 조직 기능성을 위한 방법 및 조성물
US7585865B2 (en) * 2006-07-21 2009-09-08 The Penn State Research Foundation Protein kinase C zeta inhibition to treat vascular permeability
CA2657338C (en) * 2006-07-21 2013-10-22 Cristalia Produtos Quimicos Farmaceuticos Ltda. Anti-inflammatory and antiallergic cyclic peptides
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
KR102042015B1 (ko) * 2011-06-13 2019-11-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NCBI, GenBank, Accession No. AAI46647.1(2007.07.25.)*
NCBI, GenBank, Accession No. EGF28231.1(2011.04.06.)

Also Published As

Publication number Publication date
ZA201309161B (en) 2015-03-25
EP2717897A2 (en) 2014-04-16
AU2012271781C1 (en) 2017-09-21
EP2717897B1 (en) 2017-04-19
WO2012174028A3 (en) 2013-02-21
CA2838662A1 (en) 2012-12-20
DK2717897T3 (en) 2017-07-17
MX349146B (es) 2017-07-14
CN103608026A (zh) 2014-02-26
CA2838662C (en) 2018-07-24
MX2013014650A (es) 2014-01-24
CN103608026B (zh) 2016-08-24
PL2717897T3 (pl) 2017-09-29
US9248198B2 (en) 2016-02-02
AU2012271781A1 (en) 2014-01-09
US20140155314A1 (en) 2014-06-05
AU2012271781B2 (en) 2017-02-16
US20140213505A1 (en) 2014-07-31
IL229771B (en) 2019-07-31
US8912139B2 (en) 2014-12-16
ES2633343T3 (es) 2017-09-20
EP2717897A4 (en) 2015-01-07
BR112013032108B1 (pt) 2021-10-26
JP2014518211A (ja) 2014-07-28
BR112013032108A2 (pt) 2016-11-22
WO2012174028A2 (en) 2012-12-20
JP6042425B2 (ja) 2016-12-14
CN106188232A (zh) 2016-12-07
KR20140056185A (ko) 2014-05-09
CN106188232B (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
JP7378833B2 (ja) ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
DK2650007T3 (en) Use of Cell Permeable Peptide Inhibitors by the JNK Signal Transduction Pathway for the Treatment of Various Autoimmune Diseases
KR102042015B1 (ko) 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법
US20210347821A1 (en) Inhibitors of pick1 and uses thereof
Zhang et al. Differential roles of GluN2B in two types of chemical-induced long term potentiation-mediated phosphorylation regulation of GluA1 at serine 845 in hippocampal slices
JP6660966B2 (ja) Ｂ型肝炎ウイルスｘタンパク質に対するポリペプチド薬物
US20250352614A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
GB2513615A (en) Medical use
Vannini et al. CTX-CNF1 Recombinant Protein Selectively Targets Glioma Cells In Vivo. Toxins 2021, 13, 194
KR20240138585A (ko) Nampt 유래 펩타이드를 유효성분으로 포함하는 염증성 장 질환 개선, 예방 또는 치료용 조성물
KR20230068866A (ko) 결핵균의 Rv3364c 단백질에서 유래한 패혈증 치료용 펩타이드
Li Na/K-ATPase Signaling: from Bench to Bedside
Begley Therapeutic in vivo applications for PKC-modulating intracellularly-acting peptides
HK1175102B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various cardiovascular diseases
HK1174839B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231102

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231102